KIZOO Technology Capital

KIZOO Technology Capital, based in Karlsruhe, Germany, is a specialized venture capital firm with a distinct focus on the burgeoning field of rejuvenation biotechnology. Founded by Michael Greve, a prominent figure in the longevity space and founder of FOREVER HEALTH, KIZOO is deeply integrated into the ecosystem surrounding the SENS Research Foundation. This strategic alignment underscores its commitment to combating age-related diseases by supporting groundbreaking scientific advancements. The firm's mission extends beyond mere capital provision, aiming to accelerate the development of therapies that address the root causes of aging.

As an early-stage investor, KIZOO primarily targets seed and Series A rounds, often serving as the crucial first institutional investor for promising startups. Their investment philosophy is highly hands-on, offering comprehensive mentoring, strategic guidance, and access to a robust network of scientific experts, entrepreneurs, and industry leaders. KIZOO typically deploys initial investments ranging from €500,000 to €5 million, which translates to approximately $540,000 to $5.4 million, demonstrating their capacity to provide substantial early-stage capital. This financial commitment is complemented by their operational support, which is designed to help nascent companies navigate the complex landscape of biotech development, from R&D to clinical trials.

KIZOO's unique value proposition lies in its deep domain expertise and long-term vision for a future free from age-related suffering. They are not just financial backers but active partners, leveraging their profound understanding of rejuvenation science to identify and nurture companies with the highest potential for impact. Their portfolio includes pioneering firms like Mogling Bio and Revel Pharmaceuticals, which are at the forefront of developing novel therapeutics. By concentrating solely on rejuvenation biotech, KIZOO has cultivated a specialized ecosystem that provides unparalleled support to its portfolio companies, positioning them for success in a field poised for significant growth and societal transformation.